Advertisement

Treatment of Childhood Acute Nonlymphocytic Leukemia with Individually Scheduled High Doses of Cytarabine: Preliminary Results of Study ANLL-82 of the Dutch Childhood Leukemia Study Group (DCLSG)

  • K. Hählen
  • A. van der Does-van den Berg
  • L. P. Colly
  • L. A. Smets
  • J. A. J. M. Taminiau
  • J. M. Vossen
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 30)

Abstract

Experimental studies in animals have shown that high doses of cytosine arabinoside (HDARA-C) induce synchronization and possible recruitment of leukemic cells. Administration of a second HDARA-C injection at the moment of maximal accumulation of cells in S-phase resulted in the most effective reduction (one log) of leukemic cells [1]. In a pilot study (ANLL-80) of 24 children with acute nonlymphocytic leukemia (ANLL), 12 injections of HDARA-C were administered at 24-h intervals, followed by two injections of adriamycin, which resulted in a remission rate of 71%. Without further treatment, however, early relapses occurred in the majority of these children. Cell kinetic studies in children with relapsed ANLL have shown a considerable range in the proliferative status of their disease, measured by flow cytometry. The percentage of cells in S-phase in the bone marrow (BM) at the time of relapse varied between 3.5% and 14%. An inverse relationship between the percentage of cells in S-phase at relapse and the time interval up to maximal accumulation of cells in S-phase after one injection of HDARA-C (1 g/m2) was established. The correlation between these two parameters was laid down in a “calibration curve” [2]. The current protocol, ANLL-82, with an individually scheduled induction course consisting of 12 injections of HDARA-C and one injection of adriamycin, is based on these findings. In children in remission this was followed by allogeneic bone marrow transplantation (BMT) or maintenance treatment according to the VAPA-10 protocol [3].

Keywords

Allogeneic Bone Marrow Transplantation Continuous Complete Remission Compatible Donor Evaluable Child Cell Kinetic Study 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Colly LP, Bekkum DW van, Hagenbeek A (1984) Enhanced tumor load reduction after chemotherapy induced recruitment and synchronization in a slowly growing rat leukemia model ( BNML) for human acute myelocytic leukemia. Leukemia Res 8: 953–964CrossRefGoogle Scholar
  2. 2.
    Smets LA, Taminiau J, Hählen K, et al. (1983) Cell kinetic responses in childhood acute non-lymphocytic leukemia during high dose therapy with cytosine-arabinoside. Blood 61: 79–85PubMedGoogle Scholar
  3. 3.
    Weinstein HJ, Mayer RJ, Rosenthal DS, et al. (1980) Treatment of acute myelogenous leukemia in children and adults. N Engl J Med 303: 473–478PubMedCrossRefGoogle Scholar
  4. 4.
    Steuber CP (1981) Therapy in childhood acute non-lymphocytic leukemia (ANLL): evolution of current concepts of chemotherapy. Am J Pediatr Hematol Oncol 3: 379–388PubMedCrossRefGoogle Scholar
  5. 5.
    Creutzig U, Ritter J, Riehm H, et al. (1985) Improved treatment results in childhood acute myelogenous leukemia: a report of the Germancooperative study AML-BFM-78. Blood 65: 298–304PubMedGoogle Scholar
  6. 6.
    Baehner RL, Bernstein ID, Sather H, et al. (1979) Improved remission rate with D-ZAPO but unimproved remission duration with addition of immunotherapy to chemotherapy in previously untreated children with ANLL. Med Pediatr Oncol 7: 127–139PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • K. Hählen
    • 1
  • A. van der Does-van den Berg
  • L. P. Colly
  • L. A. Smets
  • J. A. J. M. Taminiau
  • J. M. Vossen
  1. 1.Dutch Childhood Leukemia Study GroupThe HagueThe Netherlands

Personalised recommendations